Y-Biologics: utilizing innate assembly mechanisms in cell lines to create bispecific antibodies

Through its innovative, bispecific antibody platform ALiCE, Y-Biologics is discovering and developing next-generation immuno-oncology therapeutics.

Sep 12, 2019
Page of


Wai Bio Logics is representing the Republic of Korea antibody company specialized in antibody drug since its inception has focused on research and development. Based on the research and development that began in 2007, we have successfully built our unique human antibody library Y-max ABL, a new dual antibody platform technology ALiCE, and based on this, we have developed a variety of new antibody drugs to become a leader in the global market for cancer drugs. Every effort is made to leap.

No comments yet.